Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pazopanib 2 week · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part I and 2 week dosing Part II | OTHER | Part I - bevacizumab 3 infusions at 2 week intervals Part II - pazopanib dosing 2 weeks in 3-week cycles |
| Part I and 3 week dosing Part II | OTHER | Part I - bevacizumab 3 infusions at 2 week interval, Part II - pazopanib dosing 3 weeks in 3-week cycles |
| Name | Type | Description |
|---|---|---|
| Bevacizumab | DRUG | Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I |
| Pazopanib 2 week | DRUG | Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1). Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons. |
| Pazopanib 3 week | DRUG | Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1). Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons. |
Inclusion Criteria: * Histologically (any histological subtype) or cytologically confirmed unresectable RCC with a clear cell component. * Experienced documented evidence of radiological progression based on Response Evaluation Criteria in Solid Tumors \[RECIST\] while on first line (or greater) RC...
Pazopanib 2 week is being studied in renal cell carcinoma, a type of kidney cancer. It is an intermittent dosing regimen of pazopanib evaluated in a Phase 1 pharmacodynamic trial in patients with renal cell carcinoma. The trial enrolled 11 adults in the United Kingdom.
Pazopanib 2 week targets FGFR1, FGFR3, CSF1R, PDGFRB, PDGFRA, and KIT. It is a small molecule inhibitor of these receptor tyrosine kinases. This multi-target profile is intended to block signaling pathways involved in tumor growth and angiogenesis in renal cell carcinoma.
Pazopanib 2 week is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program evaluating this intermittent pazopanib dosing schedule in renal cell carcinoma.
Pazopanib 2 week is in Phase 1 clinical development. It is investigational and has not been approved for any indication. The Phase 1 program consists of one completed trial in renal cell carcinoma.
Pazopanib 2 week has been evaluated in one completed Phase 1 trial, NCT00992121, titled an open-label pharmacodynamic study of bevacizumab and pazopanib in renal cell carcinoma. The trial enrolled 11 participants in the United Kingdom and included a controlled, randomized design without double blinding.